CYT-503

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameCYT-503

Drug Alias NameiPSCs-derived GPC3 CAR NK therapy（Cytovia Therapeutics/National Cancer Institute）CYT-503

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derived +[4]

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsGlypican-3 modulators

TargetsGlypican-3

Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsLiver Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCytovia Inc

China Registration ClassN/A

Develop Information

Active CompaniesCytovia Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursOvarian NeoplasmsLiver Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A